scholarly journals Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

2021 ◽  
Vol 27 (3) ◽  
pp. S49
Author(s):  
Karen Sweiss ◽  
Eric Wenzler ◽  
Hung Nguyen ◽  
Avadhut Joshi ◽  
Rosa F. Yeh ◽  
...  
Keyword(s):  
Allogeneic Transplant

scholarly journals Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

2021 ◽  
Vol 27 (3) ◽  
pp. S150
Author(s):  
Vanessa E Kennedy ◽  
Gavin Hui ◽  
Daria Gaut ◽  
Varun Mittal ◽  
Caspian Oliai ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hypomethylating Agents ◽  
Allogeneic Transplant ◽  
Acute Myeloid

Emergence of Cunninghamella As a Pathogenic Invasive Mold Infection in Allogeneic Transplant Recipients

2013 ◽  
Vol 13 (5) ◽  
pp. 622-628 ◽  
Author(s):  
Lynne Strasfeld ◽  
Luis Espinosa-Aguilar ◽  
James L. Gajewski ◽  
Peter Stenzel ◽  
Agustin Pimentel ◽  
...  
Keyword(s):  
Transplant Recipients ◽  
Allogeneic Transplant

scholarly journals Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High-Risk Allogeneic Transplant Recipients

2017 ◽  
Vol 23 (3) ◽  
pp. S451-S452
Author(s):  
Sheila Serafino ◽  
Navneet S. Majhail ◽  
Julie Curtis ◽  
Laura Bernhard ◽  
Sharon Caroniti ◽  
...  
Keyword(s):  
High Risk ◽  
Transplant Recipients ◽  
Allogeneic Transplant

Who Should Receive an Allogeneic Transplant in First Complete Remission?

2020 ◽  
Vol 20 ◽  
pp. S48-S51
Author(s):  
Josep-Maria Ribera ◽  
Eulàlia Genescà ◽  
Jordi Ribera
Keyword(s):  
Complete Remission ◽  
Allogeneic Transplant ◽  
First Complete Remission

scholarly journals Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine

2018 ◽  
Vol 2 (11) ◽  
pp. 1198-1206 ◽  
Author(s):  
Andrew C. Harris ◽  
Jaap J. Boelens ◽  
Kwang Woo Ahn ◽  
Mingwei Fei ◽  
Allistair Abraham ◽  
...  
Keyword(s):  
Allogeneic Transplant ◽  
Transplant Outcomes ◽  
Key Points ◽  
Related Mortality

Key Points Children receiving BuFlu for nonmalignant conditions experienced less toxicity than those receiving BuCy, but survival was comparable. Children with malignancy had shorter postrelapse survival with BuFlu than BuCy; transplant-related mortality and relapse were similar.

Sign in / Sign up

Export Citation Format

Share Document